Search
OSI-461
go.drugbank.com/drugs/DB05415InvestigationalOSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).
MRx-4DP0004
go.drugbank.com/drugs/DB15751InvestigationalMRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.
Mixtures: BİOBER-ZN ORAL SÜSPANSİYON İÇEREN FLAKON, 5 ADETErtiprotafib
go.drugbank.com/drugs/DB06521ExperimentalIn insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test. … Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes.
Categories: Heterocyclic Compounds, 1-RingLX201
go.drugbank.com/drugs/DB04943InvestigationalLX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. … The implant is being developed clinically for the prevention of rejection in corneal transplantation. It is being developed by Lux Biosciences, Inc.
Daglutril
go.drugbank.com/drugs/DB05796InvestigationalDaglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.
Categories: Heterocyclic Compounds, 2-RingSynonyms: ((3S)-3-{1-((2R)-2-Ethoxycarbonyl-4-phenylbutyl)cyclopentanecarboxamido}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)acetic acidSuccinobucol
go.drugbank.com/drugs/DB05399InvestigationalAGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary
PMI-001
go.drugbank.com/drugs/DB05730ExperimentalIt is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis … PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.
Human Menstrual Blood-derived Stem Cells
go.drugbank.com/drugs/DB15738InvestigationalBecause this is a non-invasive way to obtain stem cells, it is simple and easy to obtain the stem cells with an absence of ethical issues that may come from obtaining stem cells of the embryonic kind. … MenSCs are special compared to older methods of adult stem cell extraction such as bone marrow stem cell extraction because MenSC extraction is a non-invasive method.
FP0011
go.drugbank.com/drugs/DB05090ExperimentalFP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). … It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.